Company profile: Transition Bio
1.1 - Company Overview
Company description
- Provider of condensate technology for drug discovery and diagnostics, offering PhaseScanTM, a microfluidics-based high-throughput molecular screen to identify drug candidates and mechanisms of action; CelPhaseTM, high-content cellular imaging to visualize condensates in disease models and patient samples for target validation; and DeePhaseTM, an AI engine using proprietary datasets for target discovery and hit identification.
Products and services
- CelPhaseTM: High-content cellular imaging technology that visualizes condensates in disease cell models and patient samples, aiding in target validation
- DeePhaseTM: Machine learning–driven artificial intelligence engine utilizing proprietary datasets for drug discovery activities, including target discovery and hit identification
- PhaseScanTM: Microfluidics-based high-throughput molecular screen that is used to identify drug candidates and their mechanisms of action
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Transition Bio
Arxspan
HQ: United States
Website
- Description: Provider of a platform-independent suite of applications with US cloud-based web-delivery for project based research and development collaboration in the pharmaceutical, biotechnology, or chemistry industry, enabling tracking of internal research, management of incoming CRO data, and integration with existing enterprise knowledge management tools via a web-based user interface.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arxspan company profile →
NTx
HQ: United States
Website
- Description: Provider of a proprietary host-independent biological manufacturing and development platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NTx company profile →
Formation Bio
HQ: United States
Website
- Description: Provider of a drug development platform and AI-driven tools to accelerate and optimize clinical trials and drug discovery. Offerings include an end-to-end platform leveraging proprietary technology, a clinical trial engine to improve recruitment, data collection and monitoring, and a universal data platform centralizing clinical data for rapid application creation and trial design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Formation Bio company profile →
Chemos
HQ: Germany
Website
- Description: Provider of ready-to-use solutions for laboratories and the chemical industry, offering raw materials for organic synthesis, active ingredients for the pharmaceutical and food industries, and various catalysts and crosslinkers; also provides manual filling lines for solid and liquid.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chemos company profile →
Castor
HQ: The Netherlands
Website
- Description: Provider of a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Castor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Transition Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Transition Bio
2.2 - Growth funds investing in similar companies to Transition Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Transition Bio
4.2 - Public trading comparable groups for Transition Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →